Because BRD9 is overexpressed in ovarian cancer, and targeting BRD9 sensitizes ovarian cancer to PARP inhibition and cisplatin, we show that BRD9 is a promising target to overcome therapeutic resistance in this disease. The gene discussed is BRD9; the disease is ovarian carcinoma.